Fintel reports that on May 30, 2025, Goldman Sachs initiated coverage of DexCom (NasdaqGS:DXCM) with a Buy recommendation.

DexCom Inc. closed 29.37% below its 52-week high of $121.47, which the company achieved on May 31st.

Biotech companies are using a new set of artificial intelligence products to hasten drug discovery and other scientific ...

DexCom, a global leader in glucose biosensing systems, stands out for its innovative continuous glucose monitoring (CGM) ...

Goldman Sachs has initiated coverage of diabetes technology stocks Insulet (NASDAQ:PODD) and Dexcom (NASDAQ:DXCM) with Buy ratings, citing strong long-term growth prospects in both the insulin ...

The S&P 500 Index ($SPX) (SPY) today is down -0.40%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.23%, and the ...

Artificial intelligence (AI) can enhance insulin dosing accuracy for hospitalized patients with type 2 diabetes (T2D), ...

The stock's fall snapped a two-day winning streak.

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

Gwyneth Paltrow is once again at the center of social media buzz, for what fans believe may be a health-related device ...

Medtronic (NYSE:MDT) announced today that it intends to separate its Diabetes business into a new standalone company.